Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein

Completed · Phase 1

Conditions studied: Parkinson Disease, Multisystem Atrophy, Healthy Volunteer

In brief

The overall goal of this protocol is to: Evaluate \[18F\]UCB-2897 as an α-synuclein targeted radiopharmaceutical. The primary objective is: • Confirm a specific α -synuclein signal with \[18F\]UCB-2897 in participants with PD and/or MSA relative to healthy volunteers Secondary and exploratory objectives are: * Determine the safety and tolerability of microdose \[18F\]UCB-2897 * Evaluate preliminary dosimetry of \[18F\]UCB-2897 Additional exploratory objectives are: * Determine the pharmacokinetics / metabolism of \[18F\]UCB-2897 * Determine the optimal imaging protocol for \[18F\]UCB-2897

Key facts

Study ID
NCT05274568
Run by
Invicro
People needed
5
Starts
2022-01-31
Expected to finish
2023-10-25
Last updated by the study team
2025-02-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.